$EOLS
Evolus Inc Stock $eols

$eols Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000157056224000041 Filed on March 07, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$59.33M	$61.00M	$202.1M
YoY Change	42.21%	39.76%	35.98%
Cost Of Revenue	$18.07M	$19.27M	$61.56M
YoY Change	48.75%	44.13%	10.15%
Gross Profit	$41.27M	$41.73M	$140.5M
YoY Change	39.53%	37.83%	51.54%
Gross Profit Margin	69.55%	68.41%	69.54%
Selling, General & Admin	$45.12M	$43.06M	$164.9M
YoY Change	20.7%	17.23%	16.29%
% of Gross Profit	109.35%	103.18%	117.38%
Research & Development	$2.078M	$6.808M	$6.556M
YoY Change	50.47%	405.04%	38.25%
% of Gross Profit	5.04%	16.31%	4.67%
Depreciation & Amortization	$1.409M	$1.373M	$5.133M
YoY Change	17.22%	33.69%	37.91%
% of Gross Profit	3.41%	3.29%	3.65%
Operating Expenses	$47.20M	$51.24M	$171.5M
YoY Change	21.76%	31.03%	17.0%
Operating Profit	-$8.922M	-$9.510M	-$49.23M
YoY Change	-25.9%	7.73%	-24.64%
Interest Expense	$4.702M	-$3.784M	$13.83M
YoY Change	68.59%	48.16%	52.05%
% of Operating Profit
Other Income/Expense, Net	$45.00K	$694.0K	$696.0K
YoY Change	-218.42%	726.19%	-7833.33%
Pretax Income	-$13.06M	-$11.73M	-$61.51M
YoY Change	-11.55%	-10.54%	-17.23%
Income Tax	$47.00K	$106.0K	$176.0K
% Of Pretax Income
Net Earnings	-$13.11M	-$11.83M	-$61.69M
YoY Change	-11.37%	-10.13%	-17.1%
Net Earnings / Revenue	-22.09%	-19.4%	-30.52%
Basic Earnings Per Share	-$0.22		-$1.08
Diluted Earnings Per Share	-$0.22	-$0.21	-$1.08
COMMON SHARES
Basic Shares Outstanding	57.94M shares	57.15M shares	56.92M shares
Diluted Shares Outstanding	58.80M shares		56.92M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$96.96M	$62.84M	$62.84M
YoY Change	208.17%	16.53%	16.53%
Cash & Equivalents	$96.96M	$62.84M	$62.84M
Short-Term Investments
Other Short-Term Assets	$1.842M	$2.356M	$8.056M
YoY Change	15.85%	40.41%	44.37%
Inventory	$11.55M	$11.00M	$11.00M
Prepaid Expenses	$5.678M	$5.700M
Receivables	$34.24M	$30.53M	$30.53M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$150.3M	$112.4M	$112.4M
YoY Change	78.71%	11.53%	11.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.088M	$2.087M	$7.850M
YoY Change	-19.54%	-20.22%	72.04%
Goodwill	$21.21M	$21.21M
YoY Change	0.0%	0.0%
Intangibles	$46.59M	$47.11M
YoY Change	-2.79%	-3.06%
Long-Term Investments
YoY Change
Other Assets	$409.0K	$409.0K	$409.0K
YoY Change	-84.75%	-85.46%	-85.46%
Total Long-Term Assets	$75.91M	$76.58M	$76.58M
YoY Change	-0.31%	-0.78%	-0.78%
TOTAL ASSETS
Total Short-Term Assets	$150.3M	$112.4M	$112.4M
Total Long-Term Assets	$75.91M	$76.58M	$76.58M
Total Assets	$226.2M	$189.0M	$189.0M
YoY Change	41.15%	6.19%	6.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.22M	$4.271M	$4.271M
YoY Change	10.12%	-52.2%	-52.2%
Accrued Expenses	$25.05M	$33.81M	$24.16M
YoY Change	13.32%	36.38%	9.29%
Deferred Revenue	$8.708M	$11.03M
YoY Change	24.67%	22.44%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$46.80M	$48.29M	$48.29M
YoY Change	15.05%	3.83%	3.83%
LONG-TERM LIABILITIES
Long-Term Debt	$120.6M	$120.4M	$120.4M
YoY Change	67.44%	67.45%	67.45%
Other Long-Term Liabilities	$40.26M	$41.01M	$41.01M
YoY Change	-0.68%	-0.16%	-0.16%
Total Long-Term Liabilities	$160.9M	$161.4M	$161.4M
YoY Change	42.91%	42.86%	42.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$46.80M	$48.29M	$48.29M
Total Long-Term Liabilities	$160.9M	$161.4M	$161.4M
Total Liabilities	$207.7M	$209.7M	$209.7M
YoY Change	35.52%	31.48%	31.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$572.1M	-$559.0M
YoY Change	11.72%	12.4%
Common Stock	$1.000K	$1.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.44M	-$20.69M	-$20.69M
YoY Change
Total Liabilities & Shareholders Equity	$226.2M	$189.0M	$189.0M
YoY Change	41.15%	6.19%	6.19%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$13.11M	-$11.83M	-$61.69M
YoY Change	-11.37%	-10.13%	-17.1%
Depreciation, Depletion And Amortization	$1.409M	$1.373M	$5.133M
YoY Change	17.22%	33.69%	37.91%
Cash From Operating Activities	-$10.62M	$813.0K	-$34.01M
YoY Change	-48.44%	-109.27%	-59.95%
INVESTING ACTIVITIES
Capital Expenditures	$256.0K	$361.0K	$473.0K
YoY Change	12.78%	-74.05%	-70.77%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$797.0K	-$361.0K	-$1.627M
YoY Change	55.97%	-74.05%	-44.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$45.66M	23.52M	$44.64M
YoY Change	-3661.78%	-1651.58%	-1176.72%
NET CHANGE
Cash From Operating Activities	-$10.62M	813.0K	-$34.01M
Cash From Investing Activities	-$797.0K	-361.0K	-$1.627M
Cash From Financing Activities	$45.66M	23.52M	$44.64M
Net Change In Cash	$34.12M	23.97M	$8.916M
YoY Change	-251.92%	-305.24%	-109.66%
FREE CASH FLOW
Cash From Operating Activities	-$10.62M	$813.0K	-$34.01M
Capital Expenditures	$256.0K	$361.0K	$473.0K
Free Cash Flow	-$10.87M	$452.0K	-$34.48M
YoY Change	-47.77%	-104.45%	-60.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	55887000	usd
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001570562
CY2023	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2022	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38381
CY2023	dei	Entity Registrant Name EntityRegistrantName	EVOLUS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-1385614
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	520 Newport Center Dr., Suite 1200
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Newport Beach
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92660
CY2023	dei	City Area Code CityAreaCode	949
CY2023	dei	Local Phone Number LocalPhoneNumber	284-4555
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 par value per share
CY2023	dei	Trading Symbol TradingSymbol	EOLS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	404700000	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57943622	shares
CY2023	dei	Auditor Firm AuditorFirmId	42
CY2023	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2023	dei	Auditor Location AuditorLocation	Irvine, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62838000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53922000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	30529000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	22448000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	10998000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	18852000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5700000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3902000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2356000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1678000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	112421000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	100802000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2087000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2616000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5763000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1947000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	47110000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	48597000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	21208000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	21208000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	409000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2813000	usd
CY2023Q4	us-gaap	Assets Assets	188998000	usd
CY2022Q4	us-gaap	Assets Assets	177983000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	4271000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8935000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33813000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24794000	usd
CY2023Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	0	usd
CY2022Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	5000000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1377000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1320000	usd
CY2023Q4	eols	Contingent Royalty Obligation Payableto Related Party Current ContingentRoyaltyObligationPayabletoRelatedPartyCurrent	8830000	usd
CY2022Q4	eols	Contingent Royalty Obligation Payableto Related Party Current ContingentRoyaltyObligationPayabletoRelatedPartyCurrent	6460000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	48291000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	46509000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4810000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1224000	usd
CY2023Q4	us-gaap	Contractual Obligation ContractualObligation	36200000	usd
CY2022Q4	us-gaap	Contractual Obligation ContractualObligation	39850000	usd
CY2023Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	120359000	usd
CY2022Q4	us-gaap	Secured Long Term Debt SecuredLongTermDebt	71879000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	27000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	22000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	209687000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	159484000	usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57820621	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57820621	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56260570	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56260570	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	1000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	538716000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	516129000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-427000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-337000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-558979000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-497294000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-20689000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	18499000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	188998000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	177983000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	202085000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	148616000	usd
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	6556000	usd
CY2023	eols	Research And Development In Process1 ResearchAndDevelopmentInProcess1	8869000	usd
CY2022	eols	Research And Development In Process1 ResearchAndDevelopmentInProcess1	2000000	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-4257000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-5755000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5133000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3722000	usd
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	251318000	usd
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	213946000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-49233000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-65330000	usd
CY2023	us-gaap	Investment Income Net InvestmentIncomeNet	860000	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	119000	usd
CY2023	us-gaap	Interest Expense InterestExpense	13832000	usd
CY2022	us-gaap	Interest Expense InterestExpense	9097000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	696000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61509000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-74317000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	176000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	95000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-61685000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-74412000	usd
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-90000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-337000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-61775000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-74749000	usd
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.08
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.08
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.33
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.33
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56918721	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56918721	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	56065297	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	56065297	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	81876000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	539000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	10833000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-337000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	18499000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	224000	usd
CY2023	eols	Stock Issued During Period Value Issued For License Supply And Distribution Agreement StockIssuedDuringPeriodValueIssuedForLicenseSupplyAndDistributionAgreement	5905000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	16458000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-61685000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-61685000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-90000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-20689000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-61685000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-74412000	usd
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5133000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3722000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	16458000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	10833000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1440000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1598000	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	734000	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	775000	usd
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1116000	usd
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1086000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-18000	usd
CY2023	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	4257000	usd
CY2022	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	5755000	usd
CY2023	eols	Non Cash In Research And Development In Process Expenses NonCashInResearchAndDevelopmentInProcessExpenses	4429000	usd
CY2022	eols	Non Cash In Research And Development In Process Expenses NonCashInResearchAndDevelopmentInProcessExpenses	0	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-4193000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10688000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9521000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	9389000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1798000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1180000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	864000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-4854000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1017000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	968000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	9019000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-5199000	usd
CY2023	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	5000000	usd
CY2022	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	15000000	usd
CY2023	eols	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-907000	usd
CY2022	eols	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-977000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34008000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-84912000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	473000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1618000	usd
CY2023	us-gaap	Payments For Software PaymentsForSoftware	1154000	usd
CY2022	us-gaap	Payments For Software PaymentsForSoftware	1321000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1627000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2939000	usd
CY2023	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	5537000	usd
CY2022	eols	Payments Of Contingent Royalty Obligation PaymentsOfContingentRoyaltyObligation	4185000	usd
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	50000000	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	46000	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	500000	usd
CY2023	eols	Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan	224000	usd
CY2022	eols	Proceeds From Payments For Issuance Of Common Stock In Connection With Equity Incentive Plan ProceedsFromPaymentsForIssuanceOfCommonStockInConnectionWithEquityIncentivePlan	539000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	44641000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4146000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-90000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-337000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	8916000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-92334000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53922000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146256000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	62838000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53922000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	12708000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	7999000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	117000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	76000	usd
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4550000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	usd
CY2023	us-gaap	Stock Issued1 StockIssued1	1476000	usd
CY2022	us-gaap	Stock Issued1 StockIssued1	0	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-49233000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-61685000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34008000	usd
CY2023	eols	License Supply And Distribution Agreement Upfront Payment In Process Research And Development Expense LicenseSupplyAndDistributionAgreementUpfrontPaymentInProcessResearchAndDevelopmentExpense	4441000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	62838000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-558979000	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is required to make certain estimates and assumptions in order to prepare consolidated financial statements in conformity with GAAP. Such estimates and assumptions affect the reported consolidated financial statements. These estimates include, but are not limited to net revenues, allowance for doubtful accounts, fair value measurements, inventory valuations and stock-based compensation, among others. Management bases estimates on historical experience and on assumptions that management believes are reasonable. The Company’s actual results could differ materially from those estimates.</span></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an agreement (the “Daewoong Agreement”) with Daewoong Pharmaceutical Co. Ltd. (“Daewoong”), pursuant to which the Company received an exclusive distribution license to Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from Daewoong for aesthetic indications in the United States, European Union, United Kingdom, members of the European Economic Area, Switzerland, Canada, Australia, New Zealand, and South Africa, as well as co-exclusive distribution rights with Daewoong in Japan. Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is manufactured by Daewoong in a facility in South Korea. The Company also has the option to negotiate first with Daewoong to secure a distribution license for any product that Daewoong directly or indirectly develops or commercializes that is classified as an injectable botulinum toxin (other than Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) in a territory covered by the Daewoong Agreement. The Company relies on Daewoong, its exclusive and sole supplier, to manufacture Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Any termination or loss of significant rights, including exclusivity, under the Daewoong Agreement would materially and adversely affect the Company’s commercialization of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Commitments and Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10. Medytox/Allergan Settlement Agreements and Daewoong Arrangement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company commercially launched Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the United States in May 2019 and in Canada through its distribution partner in October 2019. The Company also began commercially launching Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Europe in September 2022 and, as such, has a limited history of sales in those markets. If any previously granted approval to market and sell Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is retracted or the Company is denied approval or approval is delayed by regulators in any other jurisdictions, it may have a material adverse impact on the Company’s business and its consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to companies in the pharmaceutical industry including, but not limited to, dependency on the commercial success of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company’s sole commercial product, significant competition within the medical aesthetics industry, its ability to maintain regulatory approval of Jeuveau</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, third party litigation and challenges to its intellectual property, uncertainty of broad adoption of its product by aesthetic practitioners and patients, its ability to in-license, acquire or develop additional product candidates and to obtain the necessary approvals for those product candidates, and the need to scale manufacturing capabilities over time.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any disruption and volatility in the global capital markets, including caused by other events, such as public health crises, increased inflation and rising interest rates, and geopolitical conflicts, including the military conflict between Russia and Ukraine and the ongoing conflict in the Middle East, may increase the Company’s cost of capital and adversely affect its ability to access financing when and on terms that the Company desires. Any of these events could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents and accounts receivable. Substantially all of the Company’s cash is held by financial institutions that management believes are of high credit quality. Such deposits may, at times, exceed federally insured limits. To date, the Company has not experienced any losses associated with this credit risk and continues to believe that this exposure is not significant. The Company invests, or plans to soon invest, its excess cash, in line with its investment policy, primarily in money market funds and debt instruments of U.S. government agencies. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s accounts receivable is derived from customers located principally in the United States. Concentrations of credit risk with respect to trade receivables are limited due to the Company’s credit evaluation process. The Company does not typically require collateral from its customers. Credit losses historically have not been material. The Company continuously monitors customer payments and maintains an allowance for credit losses based on its assessment of various factors including historical experience, age of the receivable balances, and other current economic conditions or other factors that may affect customers’ ability to pay.</span></div>
CY2023	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11033000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9011000	usd
CY2023	eols	Rebates And Coupons Credits And Payments RebatesAndCouponsCreditsAndPayments	32511000	usd
CY2022	eols	Rebates And Coupons Credits And Payments RebatesAndCouponsCreditsAndPayments	22759000	usd
CY2023	eols	Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability	30489000	usd
CY2022	eols	Payments For Provisions For Accrued Volume Based Rebate And Coupon Liability PaymentsForProvisionsForAccruedVolumeBasedRebateAndCouponLiability	21682000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	7868000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	7566000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1490000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	2050000	usd
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1440000	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	1598000	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	2000000	usd
CY2022	us-gaap	Allowance For Doubtful Accounts Receivable Write Offs AllowanceForDoubtfulAccountsReceivableWriteOffs	1933000	usd
CY2022	eols	Research And Development In Process1 ResearchAndDevelopmentInProcess1	2000000	usd
CY2022	eols	Research And Development In Process1 ResearchAndDevelopmentInProcess1	2000000	usd
CY2023	eols	Non Cash In Research And Development In Process Expenses NonCashInResearchAndDevelopmentInProcessExpenses	4429000	usd
CY2023Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	0	usd
CY2022Q4	us-gaap	Litigation Reserve Current LitigationReserveCurrent	5000000	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	7490000	usd
CY2022	us-gaap	Advertising Expense AdvertisingExpense	11642000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	46310000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	44740000	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	5537000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements	4185000	usd
CY2023	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-4257000	usd
CY2022	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-5755000	usd
CY2023Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	45030000	usd
CY2022Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	46310000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	70356000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	23246000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	47110000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	21208000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	21208000	usd
CY2023Q4	eols	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	91564000	usd
CY2023Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	68318000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	67712000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19115000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	48597000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	21208000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	21208000	usd
CY2022Q4	eols	Intangible Assets Gross Including Goodwill IntangibleAssetsGrossIncludingGoodwill	88920000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19115000	usd
CY2022Q4	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	69805000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	3936000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	3201000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	3082000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	3054000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	3054000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	30783000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	47110000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4072000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3350000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3657000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2618000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	13433000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7454000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	11033000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	9011000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5690000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5711000	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	33813000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	24794000	usd
CY2023Q2	eols	Debt Instrument Number Of Installments DebtInstrumentNumberOfInstallments	2	installment
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	0	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	41667000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	83333000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	125000000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4641000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	120359000	usd
CY2019Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2023Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P60M
CY2023Q3	eols	Lessee Operating Lease Abatement Period LesseeOperatingLeaseAbatementPeriod	P3M
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	4550000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	4550000	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	1164000	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	1084000	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	183000	usd
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	91000	usd
CY2023	us-gaap	Lease Cost LeaseCost	1347000	usd
CY2022	us-gaap	Lease Cost LeaseCost	1175000	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P6Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.110
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1377000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1053000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1451000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1502000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1555000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1744000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8682000	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2495000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	6187000	usd
CY2023Q4	us-gaap	Purchase Obligation PurchaseObligation	2044000	usd
CY2020Q4	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	2	complaint
CY2021Q4	eols	Loss Contingency Number Defendants Officers LossContingencyNumberDefendantsOfficers	3	officer
CY2020Q4	us-gaap	Loss Contingency Number Of Plaintiffs LossContingencyNumberOfPlaintiffs	2	plaintiff
CY2023Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	57820621	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57820621	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	4361291	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.040
CY2023Q4	eols	Common Stock Additional Capital Shares Reservedfor Future Issuance CommonStockAdditionalCapitalSharesReservedforFutureIssuance	2287649	shares
CY2022Q4	eols	Common Stock Additional Capital Shares Reservedfor Future Issuance CommonStockAdditionalCapitalSharesReservedforFutureIssuance	2249863	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2919942	shares
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	16458000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	10833000	usd
CY2021Q1	eols	Loss Contingency Settlement Agreement Manufacturing License Period LossContingencySettlementAgreementManufacturingLicensePeriod	P21M
CY2021Q1	eols	Share Issuance Agreement Percentage Of Share Dispose Per Year Period One ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodOne	0.25
CY2021Q1	eols	Share Issuance Agreement Percentage Of Share Dispose Per Year Period Two ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodTwo	0.50
CY2021Q1	eols	Share Issuance Agreement Percentage Of Share Dispose Per Year Period Three ShareIssuanceAgreementPercentageOfShareDisposePerYearPeriodThree	0.75
CY2021Q1	eols	Registration Rights Agreement Selling Period RegistrationRightsAgreementSellingPeriod	P3M
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	3657000	usd
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2618000	usd
CY2022Q4	us-gaap	Litigation Reserve LitigationReserve	5000000	usd
CY2023	eols	Payments For Inventory PaymentsForInventory	50770000	usd
CY2022	eols	Payments For Inventory PaymentsForInventory	50685000	usd
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1582000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	773000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-51004000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-66103000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-10505000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-8214000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-61509000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-74317000	usd
CY2022Q4	eols	Deferred Tax Assets Fixed Asset Depreciation DeferredTaxAssetsFixedAssetDepreciation	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5126000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2135000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	116073000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	103695000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	138000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	113000	usd
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	33000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	171000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	113000	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	1000	usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-8000	usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	4000	usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-10000	usd
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-18000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	176000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	95000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	83257000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	80494000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5442000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5168000	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2617000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2617000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	5955000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	4675000	usd
CY2023Q4	eols	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	1567000	usd
CY2022Q4	eols	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	646000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	17674000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Legal Settlements DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLegalSettlements	19203000	usd
CY2023Q4	eols	Deferred Tax Assets Research And Experimentation Capitalization DeferredTaxAssetsResearchAndExperimentationCapitalization	3415000	usd
CY2022Q4	eols	Deferred Tax Assets Research And Experimentation Capitalization DeferredTaxAssetsResearchAndExperimentationCapitalization	1100000	usd
CY2023Q4	eols	Deferred Tax Assets Fixed Asset Depreciation DeferredTaxAssetsFixedAssetDepreciation	183000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	9163000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	12343000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	7730000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	11525000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1460000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	495000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	345000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	9190000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	12365000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	27000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	22000	usd
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-12917000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-15607000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1981000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2673000	usd
CY2023	eols	Effective Income Tax Rate Reconciliation Revaluation Of Contingent Royalty Obligation EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation	1078000	usd
CY2022	eols	Effective Income Tax Rate Reconciliation Revaluation Of Contingent Royalty Obligation EffectiveIncomeTaxRateReconciliationRevaluationOfContingentRoyaltyObligation	1462000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	385000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Meals And Entertainment IncomeTaxReconciliationNondeductibleExpenseMealsAndEntertainment	358000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	218000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-3000	usd
CY2023	eols	Effective Income Tax Rate Reconciliation Officers Compensation EffectiveIncomeTaxRateReconciliationOfficersCompensation	793000	usd
CY2022	eols	Effective Income Tax Rate Reconciliation Officers Compensation EffectiveIncomeTaxRateReconciliationOfficersCompensation	-1529000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	222000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	10000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	449000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	299000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Contingencies Other IncomeTaxReconciliationTaxContingenciesOther	-449000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Contingencies Other IncomeTaxReconciliationTaxContingenciesOther	-391000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	12378000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	18169000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	176000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	95000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2924000	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2924000	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2924000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	2924000	usd
CY2023Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001570562-24-000041-index-headers.html	Edgar Link	pending
0001570562-24-000041-index.html	Edgar Link	pending
0001570562-24-000041.txt	Edgar Link	pending
0001570562-24-000041-xbrl.zip	Edgar Link	pending
eols-20231231.htm	Edgar Link	pending
eols-20231231.xsd	Edgar Link	pending
eols-20231231_g1.jpg	Edgar Link	pending
eols-20231231_g2.jpg	Edgar Link	pending
eols-20231231_def.xml	Edgar Link	unprocessable
eols-20231231_g3.jpg	Edgar Link	pending
eols-20231231_g4.jpg	Edgar Link	pending
eols-20231231_g5.jpg	Edgar Link	pending
ex-101evolus.htm	Edgar Link	pending
ex-102evolusinc.htm	Edgar Link	pending
ex-104evolusinc.htm	Edgar Link	pending
ex-105evolusinc.htm	Edgar Link	pending
ex1035.htm	Edgar Link	pending
ex1036.htm	Edgar Link	pending
ex97recoupmentpolicy.htm	Edgar Link	pending
exhibit21112312310k.htm	Edgar Link	pending
exhibit23112312310k.htm	Edgar Link	pending
exhibit31112312310k.htm	Edgar Link	pending
exhibit31212312310k.htm	Edgar Link	pending
exhibit32112312310k.htm	Edgar Link	pending
exhibit4312312310k.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
eols-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
eols-20231231_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
eols-20231231_cal.xml	Edgar Link	unprocessable
eols-20231231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EOLS
Evolus Inc Stock $eols

2024 Q1 Form 10-K Financial Statement

#000157056224000041 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS Evolus Inc Stock $eols

2024 Q1 Form 10-K Financial Statement

#000157056224000041 Filed on March 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EOLS
Evolus Inc Stock $eols